Home Careers Contact

Price: 2.93

Change: - 0.13

Day High: 3.05
Day Low: 2.90
Volume: 515,527

4:00 PM ET | Oct 18, 2017
Delayed 20 min., by eSignal.



Shareholder Tools

Press Releases

Company News
View Summary Cempra Pharmaceuticals Will Present New Data on CEM-101 and CEM-102 at the Infectious Disease Society Of America, 47th Annual Meeting
Oct 22, 2009
PDF 10.4 KB Add to Briefcase
View Summary Cempra Pharmaceuticals Initiates Phase 2/3 Clinical Study for an Oral Antibiotic to Treat Acute Bacterial Skin Structure Infections
Sep 9, 2009
PDF 8.6 KB Add to Briefcase
View Summary Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
Aug 12, 2009
PDF 9.1 KB Add to Briefcase
View Summary CEMPRA PHARMACEUTICALS CLOSES $46 MILLION SERIES C FINANCING
May 14, 2009
PDF 12.1 KB Add to Briefcase
View Summary Cempra Pharmaceuticals Inc. Announces Lead Macrolide is Active in vitro Against Clinically Significant Antibiotic-Resistant Pathogenic Organisms
Apr 28, 2009
PDF 10.3 KB Add to Briefcase
View Summary Cempra Pharmaceuticals And Biovista Enter Agreement For Macrolide Clinical Trial Design Support Studies
Sep 30, 2008
PDF 10.8 KB Add to Briefcase
View Summary Aisling Capital joins I. Wistar Morris III and Intersouth Partners as a Lead Investor in Cempra Pharmaceuticals
Oct 3, 2006
PDF 7.0 KB Add to Briefcase
View Summary Cempra Pharmaceuticals Raises $14 Million Round of Financing
Aug 16, 2006
PDF 7.1 KB Add to Briefcase
View Summary Cempra Pharmaceuticals receives exclusive rights from Optimer Pharmaceuticals for its Macrolide Antibacterial program
Apr 4, 2006
PDF 7.1 KB Add to Briefcase
Showing 231-239 of 239 Page: 1 ... 20 21 22 23 24  Previous 10
Add to Briefcase = add release to Briefcase